港股异动 | 四环医药(00460)午前涨超5% 轩悦宁®第三个适应症上市申请获NMPA批准

智通财经03-05

智通财经APP获悉，四环医药(00460)午前涨超5%，截至发稿，涨5.19%，报1.42港元，成交额1946.91万港元。消息面上，3月3日，四环医药发布公告，集团旗下非全资附属公司轩竹生物科技股份有限公司自主研发的创新药吡洛西利片(商品名：轩悦宁®)联合芳香化酶抑制剂(AI)一线治疗激素受体阳性(HR+)、人表皮生长因子受体2阴性(HER2-)(HR+/HER2-)晚期乳腺癌的新适应症上市申请...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2617259123?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-05 11:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2617259123","market":"fut","top_or_hot":-1,"title":"港股异动 | 四环医药(00460)午前涨超5% 轩悦宁®第三个适应症上市申请获NMPA批准","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，四环医药(00460)午前涨超5%，截至发稿，涨5.19%，报1.42港元，成交额1946.91万港元。消息面上，3月3日，四环医药发布公告，集团旗下非全资附属公司轩竹生物科技股份有限公司自主研发的创新药吡洛西利片(商品名：轩悦宁®)联合芳香化酶抑制剂(AI)一线治疗激素受体阳性(HR+)、人表皮生长因子受体2阴性(HER2-)(HR+/HER2-)晚期乳腺癌的新适应症上市申请...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1410327.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 四环医药(00460)午前涨超5% 轩悦宁®第三个适应症上市申请获NMPA批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 四环医药(00460)午前涨超5% 轩悦宁®第三个适应症上市申请获NMPA批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-05 11:31 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1410327.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，四环医药(00460)午前涨超5%，截至发稿，涨5.19%，报1.42港元，成交额1946.91万港元。消息面上，3月3日，四环医药发布公告，集团旗下非全资附属公司轩竹生物科技股份有限公司自主研发的创新药吡洛西利片(商品名：轩悦宁®)联合芳香化酶抑制剂(AI)一线治疗激素受体阳性(HR+)、人表皮生长因子受体2阴性(HER2-)(HR+/HER2-)晚期乳腺癌的新适应症上市申请...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1410327.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00460","symbol_name":"四环医药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1410327.html","article_id":"2617259123","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2617259123","pubTimestamp":1772681480,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，四环医药午前涨超5%，截至发稿，涨5.19%，报1.42港元，成交额1946.91万港元。消息面上，3月3日，四环医药发布公告，集团旗下非全资附属公司轩竹生物科技股份有限公司自主研发的创新药吡洛西利片联合芳香化酶抑制剂一线治疗激素受体阳性(HR+)、人表皮生长因子受体2阴性晚期乳腺癌的新适应症上市申请，已获得中国国家药品监督管理局批准上市。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"00460":"四环医药","BK1515":"抗疫概念","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1191":"制药","VT":"世界全股市ETF-Vanguard","BK1593":"医美概念股","BK1600":"工业大麻","VXUS":"国际股票ETF-Vanguard"},"translate_title":"Changes in Hong Kong stocks | Sihuan Pharmaceutical (00460) rose more than 5% before noon Xuan Yuening ® Marketing application for third indication approved by NMPA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1.5,"00460":1.5,"VT":1.5},"content_text":"智通财经APP获悉，四环医药(00460)午前涨超5%，截至发稿，涨5.19%，报1.42港元，成交额1946.91万港元。消息面上，3月3日，四环医药发布公告，集团旗下非全资附属公司轩竹生物科技股份有限公司自主研发的创新药吡洛西利片(商品名：轩悦宁®)联合芳香化酶抑制剂(AI)一线治疗激素受体阳性(HR+)、人表皮生长因子受体2阴性(HER2-)(HR+/HER2-)晚期乳腺癌的新适应症上市申请(sNDA)，已获得中国国家药品监督管理局(NMPA)批准上市。这是吡洛西利继联合氟维司群、单药治疗适应症获批后，在中国获批的第三个适应症，至此吡洛西利成为中国首个且唯一覆盖HR+/HER2-晚期乳腺癌一线、二线、后线全疗程的同类药物。吡洛西利获批适应症扩展至HR+/HER2-晚期乳腺癌一线治疗，显著扩大了患者覆盖范围，有效提升了产品的临床价值与药物可及性，为其后续销售规模增长提供了有力支撑。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2617259123","isCrawlerRequest":true}